Description of Invention: Neuronal cell death has been associated with a variety of diseases and conditions, including Alzheimer's, AIDS-related dementia, Huntington's disease, and Parkinson's disease to name a few. Neuronal cell death has also been associated with developmental retardation and learning impairments that have lifelong effects on individuals diagnosed with these conditions.
This invention discloses new Activity Dependent Neurotrophic Factor I (ADNF I) complex polypeptides. Previously, Activity Dependent Neurotrophic Factor (ADNF) polypeptides have been shown to prevent neuronal cell death. ADNF polypeptides are secreted by astroglial cells in the presence of vasoactive intestinal peptide (VIP). These new ADNF I complex polypeptides are effective for reducing neuronal cell death, for reducing oxidative stress, for reducing condition(s) associated with fetal alcohol syndrome in a subject, for enhancing learning and memory, both pre- and post-natally, and for other conditions.
With these additional ADNF I complex polypeptides it will be easier to target specific receptors in different cell types and to individually tailor drug treatment regimes to those afflicted with neurodegenerative disorders.
For Licensing Information Please Contact: Samuel Bish Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5282 Fax: 301-402-0220